Sequenom Inc has sold two additional MassARRAY systems to GlaxoSmithKline. The additional sales follow an initial MassARRAY system purchase by GlaxoSmithKline earlier this year and a collaborative project between the two companies that generated a significant portion of Sequenom's genome-wide portfolio of validated SNP assays. The MassARRAY system is Sequenom's industry leading technology platform for high-performance analysis of genetic variation.
We are very pleased with the two additional MassARRAY system installations at GlaxoSmithKline following our initial placement less than four months ago, said Toni Schuh, Sequenom's President and Chief Executive Officer. These systems are supported by the launch of our Allelotyping product for quantitative gene analysis, which complements our existing platform, software and consumable products. We are happy to see large pharmaceutical companies such as GlaxoSmithKline continuing to make a significant investment in our MassARRAY technology.
Sequenom is a leading genetics company organized into two distinct business units: Sequenom Genetic Systems and Sequenom Pharmaceuticals. The two business units combine to capitalize on the Company's high performance MassARRAY technology, SNP assay portfolio, disease gene discovery programs and extensive DNA sample repository. The genetic systems unit is dedicated to the sales and support of Sequenom's MassARRAY hardware, consumables and software product offerings, and the provision of genetic services.